via Wistar Institute
Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR).
These finding were published today in Nature.
The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.
“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs).
Existing antibiotics target essential bacterial functions, including nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. However, bacteria can acquire drug resistance by mutating the bacterial target the antibiotic is directed against, inactivating the drugs or pumping them out.
“We reasoned that harnessing the immune system to simultaneously attack bacteria on two different fronts makes it hard for them to develop resistance,” said Dotiwala.
He and colleagues focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria.
Researchers used computer modeling to screen several million commercially available compounds for their ability to bind with the enzyme, and selected the most potent ones that inhibited IspH function as starting points for drug discovery.
Since previously available IspH inhibitors could not penetrate the bacterial cell wall, Dotiwala collaborated with Wistar’s medicinal chemist Joseph Salvino, Ph.D., professor in The Wistar Institute Cancer Center and a co-senior author on the study, to identify and synthesize novel IspH inhibitor molecules that were able to get inside the bacteria.
The team demonstrated that the IspH inhibitors stimulated the immune system with more potent bacterial killing activity and specificity than current best-in-class antibiotics when tested in vitro on clinical isolates of antibiotic-resistant bacteria, including a wide range of pathogenic gram negative and gram positive bacteria. In preclinical models of gram negative bacterial infection, the bactericidal effects of the IspH inhibitors outperformed traditional pan antibiotics. All compounds tested were shown to be nontoxic to human cells.
“Immune activation represents the second line of attack of the DAIA strategy,” said Kumar Singh, Ph.D., Dotiwala lab postdoctoral fellow and first author of the study.
“We believe this innovative DAIA strategy may represent a potential landmark in the world’s fight against AMR, creating a synergy between the direct killing ability of antibiotics and the natural power of the immune system,” echoed Dotiwala.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New class of antibiotics
- A new biosynthesis method has been developed to produce antibiotics from natural substances
The use of the element fluorine to modify active substances is an important tool in modern drug development. A team at Goethe University Frankfurt has now achieved an important “first” by successfully ...
- New study explores cell receptor crucial for cardiovascular health
Cardiovascular diseases remain a leading cause of death around the world. A primary contributor to these afflictions is high blood pressure, or hypertension.
- New Weight-Loss Drugs Can Fatten Drugmakers’ Profits
A new class of treatments for obesity can have a big impact on public health and on the bottom lines of companies like Eli Lilly and Novo Nordisk ...
- Patients seeking novel weight loss drugs find a ‘wild west’ of online prescribers
With enthusiasm for a new class of weight management drugs has come dozens of telehealth companies ready to prescribe them.
- Former U.S. Treasury secretaries back drugs, climate, tax bill
Five former U.S. Treasury secretaries - four Democrats and one Republican -- on Wednesday voiced support for a proposed $430 billion drugs, energy and tax bill, saying that it would reduce costs for ...
Go deeper with Google Headlines on:
New class of antibiotics
Go deeper with Bing News on:
Drug-resistant bacterial pathogens
- University of Oxford: Antimicrobial resistant bacteria found in newborn children from low- and middle-income countries
Sepsis is a primary cause of mortality in newborns, particularly in low- and middle-income countries (LMICs). A new study coordinated by Professor Tim Walsh at the Ineos Oxford Institute for ...
- Early-life acquisition of antibiotic resistance in neonates from developing countries
Every year, almost 7 million potentially serious bacterial infections are estimated to occur in newborns, resulting in more than 550,000 annual neonatal deaths.
- Antibiotic-Resistant Bacteria Emerging in Community Settings
CREs are a group of multidrug-resistant bacteria considered an urgent health threat by the CDC because they can rapidly spread between patients, especially those who are most seriously ill and ...
- Phage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbes
For the first time, scientists have designed a phage combination therapy that can precisely target and suppress gut bacteria associated with inflammatory bowel diseases (IBD). Presented on August 4 in ...
- Bacteria-busting proteins offer potential for smarter drugs
A specific group of bacteria-killing proteins inside the immune system could hold the key to developing smarter and more effective drugs capable of eliminating certain infectious diseases including ...